February 1, 2023
Sumitomo Pharma said on January 31 that it incurred operating and net losses in April-December as an impairment loss booked in the second quarter for its Parkinson’s treatment Kynmobi (apomorphine) continued to drag down its earnings. In the nine-month period,...read more